Sorafenib in non-small cell lung cancer

Author： Zhang Jianjun   Gold Kathryn A   Kim Edward  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.9, 2012-09, pp. : 1417-1426

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Non–Small Cell Lung Cancer

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

By Okamoto Isamu   Miyazaki Masaki   Morinaga Ryotaro   Kaneda Hiroyasu   Ueda Shinya   Hasegawa Yoshikazu   Satoh Taroh   Kawada Akira   Fukuoka Masahiro   Fukino Koichi   Tanigawa Takahiko   Nakagawa Kazuhiko  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 844-853

Springer Publishing Company

Access to resources Recommend Favorite

Pemetrexed for the treatment of non-small cell lung cancer

By Genova Carlo  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 11, 2013-08 ,pp. : 1545-1558

Informa Healthcare

Access to resources Recommend Favorite

Economics of Treatments for Non-Small Cell Lung Cancer

By Chouaid Christos   Atsou Kukovi  

PharmacoEconomics, Vol. 27, Iss. 2, 2009-01 ,pp. : 113-125

Adis International

Access to resources Recommend Favorite

Taxanes for advanced non-small cell lung cancer

By Ramalingam Sakkaraiappan   Belani Chandra P  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 12, 2002-12 ,pp. : 1693-1709

Informa Healthcare

Access to resources Recommend Favorite